• Product NameBI-847325
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityBI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
• Target NameAurora Kinase inhibitor; MEK inhibitor
• CAS No. 1207293-36-4
• Calculated MW 464.56
• Formulation C29H28N4O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:CCNC(=O)C#CC1=CC2=C(C=C1)/C(=C(\C3=CC=CC=C3)/NC4=CC=C(C=C4)CN(C)C)/C(=O)N2
  Pathways:Cell Cycle/Checkpoint; MAPK; Chromatin/Epigenetic
  Receptor:Aurora A (Human); Aurora B (Xenopus laevis); Aurora C (Human); MEK1; MEK2
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 1 mg/mL (2.15 mM)DMSO: 19 mg/mL warming (40.89 mM)Water: <1 mg/mL
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1.Sini P, et al. Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases. Mol Cancer Ther. 2016 Oct;15(10):2388-2398.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting